Posts Tagged ‘FDA’

On March 22, representatives of four major groups concerned with obesity met with senior officials from the FDA to discuss the concerns about barriers to innovation in the treatment of obesity. Leaders from the Obesity Society, Obesity Action Coalition, American Society for Metabolic and Bariatric Surgery, and the American Dietetic Association met with Janet Woodcock, […]

Despite a favorable vote by an FDA advisory panel in December, Orexigen Therapeutics announced that FDA rejected their application for a new obesity treatment called Contrave (naltrexone/buproprion). Obesity Society President Jennifer Lovejoy, PhD, expressed disappointment. “In the face of such a devastating, widespread and expensive public health crisis as obesity, it is baffling that the […]

The FDA Endocrine and Metabolic Drugs Advisory committee voted 13-7 today in favor of approving a new combination product, Contrave, for the treatment of obesity by prescription. Contrave is a combination of two drugs available for other indications, buproprion and naltrexone. This decision contrasts sharply with the outcome of three prior meetings this year of […]

Adelphi, MD – FDA Advisory Committee on Endocrinologic and Metabolic Drugs advisory committee meeting to review the use of sibutramine in the treatment of obesity.  Theodore Kyle, RPh and chair of the The Obesity Society (TOS) Advocacy Task Force, presented a statement on behalf of TOS urging the panel to balance the need for effective treatments with […]